Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term tolvaptan safety and efficacy in adults with autosomal dominant polycystic kidney disease
2006-002768-24Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Tolvaptan with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Nov 2006; status: completed.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2006-002768-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002768-24.